Cobb Carla D
RiverStone Health Clinic, Billings, Montana.
Pharmacotherapy. 2014 Dec;34(12):1336-40. doi: 10.1002/phar.1503. Epub 2014 Oct 20.
Our objective was to evaluate a pharmacist-delivered comprehensive medication management (CMM) service provided to patients with psychiatric disorders. We conducted a retrospective review and analysis of medication-related data, and a return on investment cost analysis. The project consisted of 154 patients with psychiatric disorders who were referred to the CMM service by physicians, therapists, case managers, friends, or family, and were seen by the service between April 2011 and July 2013. CMM evaluates a patient's medications to ensure that they are appropriate, effective, safe, and convenient. Patients were seen by pharmacists trained in CMM and the treatment of mental illnesses, including one board-certified psychiatric pharmacist. All medications were reviewed including prescriptions, over-the-counter medications, and nutritional supplements. The patients' medication-related concerns, goals of treatment, vital signs, and laboratory studies were reviewed. Drug therapy problems such as adverse reactions, unnecessary medications, excessive doses, and poor medication adherence were identified, and written recommendations were mailed to patients and physicians within 1 week. Patients were offered follow-up in 4-6 weeks and were seen as many times as needed to resolve drug therapy problems. The 154 patients completed 256 CMM visits. A mean of 10.1 medical and psychiatric conditions and 13.7 medications/person were assessed. A mean of 5.6 drug therapy problems/patient were identified. A total net cost savings was estimated to be $90,484.00, with a mean savings of $586.55/patient. The cost of providing the service was estimated at $32,185.93. The return on investment was estimated to be 2.8; thus for every dollar spent on providing the service, $2.80 was estimated to be saved. Patients with mental illnesses may benefit from pharmacist-delivered CMM to help resolve drug therapy problems. Medication management may improve clinical outcomes and reduce costs. In addition, patients valued the opportunity to review their medications with a pharmacist.
我们的目标是评估为精神疾病患者提供的由药剂师提供的综合药物管理(CMM)服务。我们对与药物相关的数据进行了回顾性审查和分析,并进行了投资回报成本分析。该项目包括154名精神疾病患者,他们由医生、治疗师、病例管理人员、朋友或家人转介至CMM服务,并于2011年4月至2013年7月期间接受该服务。CMM评估患者的药物,以确保其合适、有效、安全且方便。患者由接受过CMM和精神疾病治疗培训的药剂师诊治,包括一名获得董事会认证的精神科药剂师。审查了所有药物,包括处方药、非处方药和营养补充剂。还审查了患者与药物相关的问题、治疗目标、生命体征和实验室检查。识别出药物治疗问题,如不良反应、不必要的药物、过量用药和药物依从性差等,并在1周内将书面建议邮寄给患者和医生。为患者提供4至6周的随访,并根据需要安排多次就诊以解决药物治疗问题。这154名患者共完成了256次CMM就诊。平均每人评估了10.1种医疗和精神疾病状况以及13.7种药物。平均每位患者识别出5.6个药物治疗问题。估计总共节省净成本90,484.00美元,平均每位患者节省586.55美元。提供该服务的成本估计为32,185.93美元。投资回报率估计为2.8;因此,每花费1美元提供该服务,估计可节省2.80美元。患有精神疾病的患者可能会从药剂师提供的CMM中受益,以帮助解决药物治疗问题。药物管理可能会改善临床结果并降低成本。此外,患者重视与药剂师一起审查其药物的机会。